During the
forecast period from 2012-2022, the growth of the ulcerative
colitis market will be driven largely by the entry of Johnson &
Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase
in the overall number of patients being treated with biologics in the US, 5EU,
Japan, and Canada.
Another key event affecting the UC market is the anticipated launch of
biosimilars, given that the patent expiry of the UC blockbusters, Remicade and
Humira are set to expire in the US in 2018 and 2016, respectively.
Overall, major barriers to the growth of the UC market include -
• Remicade
and Humira losing patent protection in the mid-forecast
• Austerity measures favoring generic prescribing
• Biosimilars are predicted to face low uptake due to the lack of regulatory
guidelines in some markets, such as the US
• In 2012, GlobalData estimates that the global UC market reached $4.2 billion
across the 10 healthcare markets covered in our forecast: the US, France,
Germany, Italy, Spain, the UK, Japan, Canada, China, and India. By the end of
the forecast period, in 2022, sales across these markets will grow steadily to
reach $6.6 billion, representing a Compound Annual Growth Rate (CAGR) of 4.8%
over the 10-year timeframe.
Highlights
Key Questions Answered
• How will the UC market (sales and patient numbers) evolve over the 10-year
forecast period from 2012 to 2022?
• Which brands and specific drug classes did physicians select for their UC
patients in 2012 and how do they foresee their prescribing behavior evolving
over the next five years?
• How will the launch of late-stage pipeline therapies such as Entyvio and
Kappaproct shape the future treatment landscape?
• What are the remaining unmet needs and opportunities for drug developers
within the UC market?
Key Findings
• The UC market has predominantly been driven by two TNF blockers, namely
J&Js Remicade and AbbVies Humira. Although these TNF blockers have
monopolized the UC market for almost a decade, the balance is about to be
tipped, with Takedas Entyvio imminently entering the market in 2014 and
J&Js Simponi launching in 2014 as well, stealing market share from Humira
and Remicade.
• Remicade and Humira will also be hit by their respective loss of patent
protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already
approved a biosimilar to Remicade, Celltrions Remsima, which will be marketed
by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory
guidelines and the current debate about indication extrapolation for
biosimilars based on a clinical trial in one indication, initial biosimilar
uptake will be low, but by the end of the forecast period, in 2022 infliximab,
adalimumab and golimumab biosimilars are forecast to become an established part
of the UC market.
• During the coming decade, Europe is expecting the approval and launch of a UC
colectomy rescue therapy, InDex Pharmaceuticals Kappaproct. Kappaproct is
targeting a small patient population group, but due to the involvement of key
gastroenterologists in the development of this therapy, it will likely be
welcomed for use in this new treatment setting, which has never been addressed
before by a pharmaceutical product. In addition, Pfizers Xeljanz is expected to
face low uptake post its estimated launch in 2017, owing to the controversy
surrounding its rejection by the EMA for its primary indication, rheumatoid
arthritis.
Scope
• Overview of UC, including epidemiology, etiology, pathophysiology, symptoms,
diagnosis, and current treatment options.
• Annualized UC therapeutics market revenue, annual cost of therapy and
treatment usage pattern data from 2012 to 2022.
• Key topics covered include strategic competitor assessment, market
characterization, unmet needs, and implications for the UC therapeutics
markets.
• Pipeline analysis: comprehensive data split across different phases, emerging
novel trends under development, and detailed analysis of late stage pipeline
drugs.
• Analysis of the current and future market competition in the global UC
therapeutics markets. Insightful review of the key industry drivers, restraints
and challenges. Each trend is independently researched to provide qualitative
analysis of its implications.
Reasons to buy
• Develop and design in-licensing and out-licensing strategies through a review
of pipeline products and technologies, and by identifying the companies with
the most robust pipeline. Additionally a list of acquisition targets included
in the pipeline product company list.
• Develop business strategies by understanding the trends shaping and driving
the global UC therapeutics markets.
• Drive revenues by understanding the key trends, innovative products and
technologies, market segments, and companies likely to impact the global UC
therapeutics markets in the future.
• Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and
create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global UC therapeutics markets from 2012-2022.
• Organize sales and marketing efforts by identifying the market categories and
segments that present maximum opportunities for consolidations, investments and
strategic partnerships.
No comments:
Post a Comment